Werewolf Therapeutics Inc (HOWL)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$0.97+2.38%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · HOWL
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
HOWL — private placement
Dated 2026-08-21
Entry into a Material Definitive Agreement Merger Agreement On August 21, 2026, Werewolf Therapeutics, Inc., a Delaware corporation (“Werewolf”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) by and among Ambros Therapeutics, Inc., a Delaware corporation (“Ambros”), Werewolf, and Wave Atlantis Merger Sub, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Werewolf (“Merger Sub”). Pursuant to the Merger Agreement, and upon the terms and subject to the…
Why it matters: Updates on strategic options may mean new partners or funding. This is important for shareholders.
Supportive ifA press release will share news about a new partnership or funding deal.
Worry ifNo new updates or partnerships announced by the end of Q3 2026.
Why it matters: Data updates on these trials can change investor confidence and future funding.
Supportive ifA press release announcing positive clinical trial results for WTX-124 or WTX-330.
Worry ifNegative trial results or delays in data release for WTX-124 or WTX-330.
Why it matters: This report will give updates on financial health and plans. It can affect investor feelings.
Watch forThe earnings report shows a smaller net loss than the previous quarter.
Also watch forThe earnings report shows a larger net loss than the previous quarter.
Why it matters: Advancements in this platform could boost the company's value and attract partnerships.
Supportive ifThe company has a new partnership or starts a clinical trial for the INDUCER platform.
Worry ifNo updates or progress reported on the INDUCER platform in the next earnings call.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$363 on $10,000 · ±3.6% | How much price usually moves either way. |
| Bad day | $895 loss on $10,000 · 8.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,594 loss on $10,000 · 85.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: More cuts in operating expenses could help make more money and improve cash flow.
Supportive ifOperating expenses go down more in Q3 2026 compared to Q2 2026.
Worry ifOperating expenses go up or stay the same without more cuts.
Why it matters: More cuts could help profits and make operations more efficient.
Supportive ifAnnouncement of further reductions in R&D or G&A expenses in the next quarter.
Worry ifOperating expenses rise or stay the same despite earlier cuts.
Why it matters: Changes in operating costs show how well the company controls spending. This impacts cash flow.
Worry ifOperating expenses decrease by more than 10% in the next quarter.
Less concerning ifOperating costs go up or stay the same compared to last quarter.
Why it matters: The merger could make Werewolf stronger in the market. It may also improve its drug pipeline.
Supportive ifThe merger closes by the first quarter of 2027 as planned.
Worry ifThe merger faces delays or fails to close due to regulatory issues.
Why it matters: Updates on cash runway are important for stability. A longer runway shows better financial health.
Supportive ifManagement confirms cash runway extends beyond Q2 2027.
Worry ifManagement lowers cash runway guidance. This shows the company may be facing financial problems.